Sotabase

Career

· TC Member IEEE IES CWAIA, IEEE Industrial Electronics Society (IES)2025–2025
· Assistant Professor, Chitkara University2024–2024
· Assistant Professor, Lovely Professional University2023–2024
· Post Doc, Université de Moncton, Moncton, Canada (Current)2023–
· Assistant Professor, Guru Nanak Dev University, Amritsar2022–2023
· Assist Prof, Guru Nanak Dev University, Amritsar2019–2022

Publications (20)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet · 2021
1,601
cited
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
Gastroenterology · 2019
308
cited
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet · 2021
270
cited
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
medRxiv · 2022
241
cited
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
The Lancet · 2021
113
cited
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet · 2023
94
cited
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
Nature Communications · 2022
73
cited
Treatment failure in coeliac disease: a practical guide to investigation and treatment of non-responsive and refractory coeliac disease.
Journal of Gastrointestinal and Liver Diseases · 2012
66
cited
A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study.
Digestive and Liver Disease · 2018
51
cited
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
The Lancet Gastroenterology and Hepatology · 2021
32
cited
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
The Lancet Gastroenterology and Hepatology · 2022
28
cited
Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey*
Scandinavian Journal of Gastroenterology · 2018
24
cited
Republished: Daily consultant gastroenterologist ward rounds: reduced length of stay and improved inpatient mortality
Postgraduate medical journal · 2011
19
cited
ADTU-06 ‘real world’ outcomes of vedolizumab over 12 months: the cross pennine multicentre experience
IBD · 2018
Effectiveness and Safety of Vedolizumab (VDZ) in IBD Patients: A Multicenter Experience of “Real World Data” From the U.K.: 688
2017
Haloperidol for delirium tremens as an adjunct treatment to benzodiazepines: experience of a hospital alcohol team
Gastrointestinal Nursing · 2018
OWE-008 Patients’ perception of faecal calprotectin testing in inflammatory bowel disease: a multi-centre prospective survey
IBD · 2018
PTH-090 A new model of consultation to facilitate a patient centred approach in the IBD clinic
Posters · 2019
PWE-065 Patients’ perception of faecal calprotectin testing in inflammatory bowel disease: results from a prospective patient based survey
Gut · 2017
Sotabase
Salil Singh | Researcher Profile | Sotabase | Sotabase